Kadagothy Husna, Nene Shweta, Amulya Etikala, Vambhurkar Ganesh, Rajalakshmi A N, Khatri Dharmendra Kumar, Singh Shashi Bala, Srivastava Saurabh
Department of Pharmaceutics, Mother Theresa Post Graduate and Research Institute of Health Sciences, Puducherry, India.
Pharmaceutical Innovation and Translational Research Lab (PITRL), Department of Pharmaceutics, National Institute of Pharmaceutical Education and Research (NIPER), Hyderabad, India.
Eur J Pharmacol. 2023 May 15;947:175668. doi: 10.1016/j.ejphar.2023.175668. Epub 2023 Mar 21.
Psoriasis is an enduring, pruritic and papulosquamous skin ailment that poses a significant burden on public health. It is mainly characterized by hyperkeratosis, acanthosis, parakeratosis, scaly and erythematous plaques. Biomarkers like interleukin-17, interleukin-12 and -23 and tumor necrosis factor-α serve as key drivers of psoriatic pathogenesis. Triggered release of pro-inflammatory cytokines from various up-regulated pathways leads to psoriatic inflammation. Several target moieties like biologics, small molecules and herbal moieties play a fundamental role in the repression of pathogenesis of psoriasis. Biologics and small molecules engaged in the management of psoriasis have been emphasized in detail. An insight into nano-carrier interventions on herbal moieties and clinical aspects of psoriasis are also highlighted. This review emphasizes various pathological targets involved in psoriasis.
银屑病是一种持久的、瘙痒性的丘疹鳞屑性皮肤病,给公共卫生带来了重大负担。它主要表现为角化过度、棘层肥厚、角化不全、鳞屑性红斑斑块。白细胞介素-17、白细胞介素-12和-23以及肿瘤坏死因子-α等生物标志物是银屑病发病机制的关键驱动因素。各种上调途径引发的促炎细胞因子的释放导致银屑病炎症。生物制剂、小分子和草药成分等几种靶向部分在抑制银屑病发病机制中发挥着重要作用。已详细强调了用于治疗银屑病的生物制剂和小分子。还重点介绍了纳米载体对草药成分的干预以及银屑病的临床方面。本综述强调了银屑病涉及的各种病理靶点。